GMR Solutions Q2 Revenue Hits $1.49B, EBITDA Falls 11.8%
GMR Solutions reported Q2 revenue growth of 3.3% but adjusted EBITDA declined due to favorable prior-year estimates.
Key points
- Q2 2026 revenue increased 3.3% year-over-year to $1.49 billion.
- Adjusted EBITDA decreased 11.8% to $285 million due to prior-year estimate adjustments.
- Full-year guidance remains at $5.89B-$6.18B revenue and $1.135B-$1.195B adjusted EBITDA.
Global Medical Response (NYSE: GMRS) delivered second-quarter 2026 revenue of $1.49 billion, marking a 3.3% year-over-year increase. The company handled 1.4 million patient encounters, including over 1.3 million ground medical services and 36,000 air medical transports. Operational volume was supported by growth in same-market revenue and disciplined cost management across its integrated service model.
Adjusted EBITDA for the quarter stood at $285 million, representing an 11.8% decline from the prior year period. Management attributed the decrease to favorable revenue estimate adjustments recorded in the previous year, specifically related to collections on claims affected by the No Surprises Act. The adjusted EBITDA margin for the quarter was 19.1%.
Full-year guidance remains unchanged
GMR Solutions reiterated its full-year 2026 financial outlook, projecting total revenue between $5.89 billion and $6.18 billion. The company expects adjusted EBITDA to fall within a range of $1.135 billion to $1.195 billion for the full fiscal year. These figures reflect management’s confidence in the stability of its core EMS operations despite payer mix shifts.
Strategic expansion drives call volume
The 911 nurse navigation program saw a 50% year-over-year increase in calls, highlighting the effectiveness of this strategic initiative. The company expanded its footprint by opening new air bases and integrating additional 911 systems. These moves aim to capture more on-scene interventions and enhance data utilization for operational efficiency.
Liquidity position supports regulatory shifts
GMR Solutions maintains a strong liquidity position with $420 million in cash, providing a buffer against regulatory and market changes. Management noted the impact of the ACA exchange subsidy expiration on payer mix and revenue recognition. The company continues to focus on technology-driven efficiency to mitigate these headwinds while sustaining its market position.
